Pharmacogenomics (PGx) is the next frontier in medication therapy management and RxGenomix was created specifically to help put it to work for everyone. RxGenomix helps healthcare providers understand the genetic-driven mechanisms behind the response to medications and navigate the implementation process of a new healthcare tool. By applying PGx testing, they can look at very specific pieces of their patients’ DNA to know, for many of the most common and critical medications, precisely which might be best for that individual, and at what dosage. Empowering healthcare providers with this knowledge has several distinct benefits including more effective overall treatment, limitation or avoidance of adverse drug events, more efficient healthcare delivery and the potential for significant cost savings. The RxGenomix solution is a key strategy to solving for the Quadruple Aim. Everyone wins. We’ve found the path to more personal healthcare and, with our enhanced approach to the application of pharmacogenomics, providers have the power to tailor treatment to the individual like never before.
Looking for a particular RxGenomix employee's phone or email?
The RxGenomix annual revenue was $7 million in 2026.
Brad Tice is the CEO of RxGenomix.
6 people are employed at RxGenomix.
RxGenomix is based in Franklin, Tennessee.
The NAICS codes for RxGenomix are [621, 51711, 517, 62, 517110, 5171, 51].
The SIC codes for RxGenomix are [80, 7375, 73, 737, 809].